Erdely Aaron, Freshour Gary, Baylis Chris
Department of Physiology and Functional Genomics, 1600 SW Archer Rd., P. O. Box 100274, University of Florida, Gainesville, FL 32610-0274, USA.
Am J Physiol Regul Integr Comp Physiol. 2006 Jan;290(1):R66-72. doi: 10.1152/ajpregu.00444.2005.
Chronic nitric oxide synthase inhibition (NOSI) causes chronic kidney disease (CKD) in the Sprague Dawley (SD) rat. We previously showed that the Wistar-Furth (WF) rats are resistant to several models of CKD and maintain renal nitric oxide (NO) production compared with SD rats, whereas low-dose NOSI caused progression of CKD in WF rats. Here, we evaluate the impact of high-dose chronic NOSI in WF and SD rats, as well as intrarenal responses to an acute pressor dose of NOSI in the normal WF. Rats were given N(G)-nitro-l-arginine methyl ester (l-NAME) (150 and 300 mg/l for 6-10 wk) in the drinking water after an initial bolus tail vein injection. Both strains showed significant reductions in total NO production with chronic l-NAME. SD given 150 mg/l l-NAME for 6 wk developed proteinuria and renal injury, whereas WF rats receiving 150 mg/l l-NAME for 6-10 wk or 300 mg/l for 6 wk developed no proteinuria and minimal renal injury. Blood pressure was significantly elevated with chronic NOSI in both strains but was higher in the SD rat. There was little impact on renal nitric oxide synthase expression with l-NAME, except that cortical endothelial nitric oxide synthase abundance increased in WF after 6 wk (150 mg/l). Micropuncture experiments with acute pressor NOSI resulted in similar increases in systemic blood pressure in SD and WF rats, whereas WF rats showed a much smaller increment in glomerular blood pressure compared with SD rats. In conclusion, WF rats do not develop renal injury after chronic NOSI at, or above, a dose that causes significant injury in the SD rat. This protection may be associated with protection from glomerular hypertension.
慢性一氧化氮合酶抑制(NOSI)可导致Sprague Dawley(SD)大鼠患慢性肾脏病(CKD)。我们之前发现,与SD大鼠相比,Wistar-Furth(WF)大鼠对多种CKD模型具有抗性,并能维持肾脏一氧化氮(NO)的生成,而低剂量的NOSI会导致WF大鼠的CKD进展。在此,我们评估高剂量慢性NOSI对WF和SD大鼠的影响,以及正常WF大鼠对急性升压剂量NOSI的肾内反应。大鼠在首次尾静脉注射推注后,饮用含N(G)-硝基-L-精氨酸甲酯(L-NAME)(150和300 mg/L,持续6 - 10周)的饮水。两种品系的大鼠在慢性给予L-NAME后,总NO生成均显著减少。给予150 mg/L L-NAME持续6周的SD大鼠出现蛋白尿和肾损伤,而接受150 mg/L L-NAME持续6 - 10周或300 mg/L持续6周的WF大鼠未出现蛋白尿且肾损伤轻微。两种品系的大鼠在慢性NOSI后血压均显著升高,但SD大鼠的血压更高。L-NAME对肾脏一氧化氮合酶表达影响较小,不过在6周后(150 mg/L),WF大鼠皮质内皮型一氧化氮合酶丰度增加。急性升压NOSI的微穿刺实验导致SD和WF大鼠的全身血压有相似程度的升高,然而与SD大鼠相比,WF大鼠肾小球血压的升高幅度要小得多。总之,在能导致SD大鼠显著损伤的剂量及以上,慢性NOSI后WF大鼠不会发生肾损伤。这种保护作用可能与免受肾小球高血压有关。